Global Artificial Intelligence-driven Drug Development 麻豆原创 Research Report 2024

Publication ID:

PB507249581

Publication Date:

July 9, 2024

Pages:

104

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Computing & Electronics [3]

Description:

Artificial intelligence (AI) has the potential to revolutionize the drug discovery process,
offering improved efficiency, accuracy, and speed.

The global Artificial Intelligence-driven Drug Development market was valued at US$ 1366.3 million in 2023 and is anticipated to reach US$ 8890.4 million by 2030, witnessing a CAGR of 30.7% during the forecast period 2024-2030.
North American market for Artificial Intelligence-driven Drug Development is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Artificial Intelligence-driven Drug Development is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Artificial Intelligence-driven Drug Development in Early Drug Discovery is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Artificial Intelligence-driven Drug Development include IBM, Exscientia, Google(Alphabet), Microsoft, Atomwise, Schrodinger, Aitia, Insilico Medicine and NVIDIA, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Artificial Intelligence-driven Drug Development, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Artificial Intelligence-driven Drug Development.
Report Scope
The Artificial Intelligence-driven Drug Development market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Artificial Intelligence-driven Drug Development market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Artificial Intelligence-driven Drug Development companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
IBM
Exscientia
Google(Alphabet)
Microsoft
Atomwise
Schrodinger
Aitia
Insilico Medicine
NVIDIA
XtalPi
BPGbio
Owkin
CytoReason
Deep Genomics
Cloud Pharmaceuticals
BenevolentAI
Cyclica
Verge Genomics
Valo Health
Envisagenics
Euretos
BioAge Labs
Iktos
BioSymetrics
Evaxion Biotech
Aria Pharmaceuticals
Segment by Type
Hardware
Software
Service
Segment by Application
Early Drug Discovery
Preclinical Phase
Clinical Phase
Regulatory Approval
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Artificial Intelligence-driven Drug Development companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Artificial Intelligence-driven Drug Development 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Hardware
1.2.3 Software
1.2.4 Service
1.3 麻豆原创 by Application
1.3.1 Global Artificial Intelligence-driven Drug Development 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Early Drug Discovery
1.3.3 Preclinical Phase
1.3.4 Clinical Phase
1.3.5 Regulatory Approval
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Artificial Intelligence-driven Drug Development 麻豆原创 Perspective (2019-2030)
2.2 Artificial Intelligence-driven Drug Development Growth Trends by Region
2.2.1 Global Artificial Intelligence-driven Drug Development 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Artificial Intelligence-driven Drug Development Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Artificial Intelligence-driven Drug Development Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Artificial Intelligence-driven Drug Development 麻豆原创 Dynamics
2.3.1 Artificial Intelligence-driven Drug Development Industry Trends
2.3.2 Artificial Intelligence-driven Drug Development 麻豆原创 Drivers
2.3.3 Artificial Intelligence-driven Drug Development 麻豆原创 Challenges
2.3.4 Artificial Intelligence-driven Drug Development 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Artificial Intelligence-driven Drug Development Players by Revenue
3.1.1 Global Top Artificial Intelligence-driven Drug Development Players by Revenue (2019-2024)
3.1.2 Global Artificial Intelligence-driven Drug Development Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Artificial Intelligence-driven Drug Development 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Artificial Intelligence-driven Drug Development Revenue
3.4 Global Artificial Intelligence-driven Drug Development 麻豆原创 Concentration Ratio
3.4.1 Global Artificial Intelligence-driven Drug Development 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Artificial Intelligence-driven Drug Development Revenue in 2023
3.5 Artificial Intelligence-driven Drug Development Key Players Head office and Area Served
3.6 Key Players Artificial Intelligence-driven Drug Development Product Solution and Service
3.7 Date of Enter into Artificial Intelligence-driven Drug Development 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Artificial Intelligence-driven Drug Development Breakdown Data by Type
4.1 Global Artificial Intelligence-driven Drug Development Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Artificial Intelligence-driven Drug Development Forecasted 麻豆原创 Size by Type (2025-2030)
5 Artificial Intelligence-driven Drug Development Breakdown Data by Application
5.1 Global Artificial Intelligence-driven Drug Development Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Artificial Intelligence-driven Drug Development Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Artificial Intelligence-driven Drug Development 麻豆原创 Size (2019-2030)
6.2 North America Artificial Intelligence-driven Drug Development 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Artificial Intelligence-driven Drug Development 麻豆原创 Size by Country (2019-2024)
6.4 North America Artificial Intelligence-driven Drug Development 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Artificial Intelligence-driven Drug Development 麻豆原创 Size (2019-2030)
7.2 Europe Artificial Intelligence-driven Drug Development 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Artificial Intelligence-driven Drug Development 麻豆原创 Size by Country (2019-2024)
7.4 Europe Artificial Intelligence-driven Drug Development 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Artificial Intelligence-driven Drug Development 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Artificial Intelligence-driven Drug Development 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Artificial Intelligence-driven Drug Development 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Artificial Intelligence-driven Drug Development 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Artificial Intelligence-driven Drug Development 麻豆原创 Size (2019-2030)
9.2 Latin America Artificial Intelligence-driven Drug Development 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Artificial Intelligence-driven Drug Development 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Artificial Intelligence-driven Drug Development 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Artificial Intelligence-driven Drug Development 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Artificial Intelligence-driven Drug Development 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Artificial Intelligence-driven Drug Development 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Artificial Intelligence-driven Drug Development 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 IBM
11.1.1 IBM Company Detail
11.1.2 IBM Business Overview
11.1.3 IBM Artificial Intelligence-driven Drug Development Introduction
11.1.4 IBM Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.1.5 IBM Recent Development
11.2 Exscientia
11.2.1 Exscientia Company Detail
11.2.2 Exscientia Business Overview
11.2.3 Exscientia Artificial Intelligence-driven Drug Development Introduction
11.2.4 Exscientia Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.2.5 Exscientia Recent Development
11.3 Google(Alphabet)
11.3.1 Google(Alphabet) Company Detail
11.3.2 Google(Alphabet) Business Overview
11.3.3 Google(Alphabet) Artificial Intelligence-driven Drug Development Introduction
11.3.4 Google(Alphabet) Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.3.5 Google(Alphabet) Recent Development
11.4 Microsoft
11.4.1 Microsoft Company Detail
11.4.2 Microsoft Business Overview
11.4.3 Microsoft Artificial Intelligence-driven Drug Development Introduction
11.4.4 Microsoft Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.4.5 Microsoft Recent Development
11.5 Atomwise
11.5.1 Atomwise Company Detail
11.5.2 Atomwise Business Overview
11.5.3 Atomwise Artificial Intelligence-driven Drug Development Introduction
11.5.4 Atomwise Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.5.5 Atomwise Recent Development
11.6 Schrodinger
11.6.1 Schrodinger Company Detail
11.6.2 Schrodinger Business Overview
11.6.3 Schrodinger Artificial Intelligence-driven Drug Development Introduction
11.6.4 Schrodinger Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.6.5 Schrodinger Recent Development
11.7 Aitia
11.7.1 Aitia Company Detail
11.7.2 Aitia Business Overview
11.7.3 Aitia Artificial Intelligence-driven Drug Development Introduction
11.7.4 Aitia Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.7.5 Aitia Recent Development
11.8 Insilico Medicine
11.8.1 Insilico Medicine Company Detail
11.8.2 Insilico Medicine Business Overview
11.8.3 Insilico Medicine Artificial Intelligence-driven Drug Development Introduction
11.8.4 Insilico Medicine Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.8.5 Insilico Medicine Recent Development
11.9 NVIDIA
11.9.1 NVIDIA Company Detail
11.9.2 NVIDIA Business Overview
11.9.3 NVIDIA Artificial Intelligence-driven Drug Development Introduction
11.9.4 NVIDIA Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.9.5 NVIDIA Recent Development
11.10 XtalPi
11.10.1 XtalPi Company Detail
11.10.2 XtalPi Business Overview
11.10.3 XtalPi Artificial Intelligence-driven Drug Development Introduction
11.10.4 XtalPi Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.10.5 XtalPi Recent Development
11.11 BPGbio
11.11.1 BPGbio Company Detail
11.11.2 BPGbio Business Overview
11.11.3 BPGbio Artificial Intelligence-driven Drug Development Introduction
11.11.4 BPGbio Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.11.5 BPGbio Recent Development
11.12 Owkin
11.12.1 Owkin Company Detail
11.12.2 Owkin Business Overview
11.12.3 Owkin Artificial Intelligence-driven Drug Development Introduction
11.12.4 Owkin Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.12.5 Owkin Recent Development
11.13 CytoReason
11.13.1 CytoReason Company Detail
11.13.2 CytoReason Business Overview
11.13.3 CytoReason Artificial Intelligence-driven Drug Development Introduction
11.13.4 CytoReason Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.13.5 CytoReason Recent Development
11.14 Deep Genomics
11.14.1 Deep Genomics Company Detail
11.14.2 Deep Genomics Business Overview
11.14.3 Deep Genomics Artificial Intelligence-driven Drug Development Introduction
11.14.4 Deep Genomics Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.14.5 Deep Genomics Recent Development
11.15 Cloud Pharmaceuticals
11.15.1 Cloud Pharmaceuticals Company Detail
11.15.2 Cloud Pharmaceuticals Business Overview
11.15.3 Cloud Pharmaceuticals Artificial Intelligence-driven Drug Development Introduction
11.15.4 Cloud Pharmaceuticals Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.15.5 Cloud Pharmaceuticals Recent Development
11.16 BenevolentAI
11.16.1 BenevolentAI Company Detail
11.16.2 BenevolentAI Business Overview
11.16.3 BenevolentAI Artificial Intelligence-driven Drug Development Introduction
11.16.4 BenevolentAI Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.16.5 BenevolentAI Recent Development
11.17 Cyclica
11.17.1 Cyclica Company Detail
11.17.2 Cyclica Business Overview
11.17.3 Cyclica Artificial Intelligence-driven Drug Development Introduction
11.17.4 Cyclica Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.17.5 Cyclica Recent Development
11.18 Verge Genomics
11.18.1 Verge Genomics Company Detail
11.18.2 Verge Genomics Business Overview
11.18.3 Verge Genomics Artificial Intelligence-driven Drug Development Introduction
11.18.4 Verge Genomics Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.18.5 Verge Genomics Recent Development
11.19 Valo Health
11.19.1 Valo Health Company Detail
11.19.2 Valo Health Business Overview
11.19.3 Valo Health Artificial Intelligence-driven Drug Development Introduction
11.19.4 Valo Health Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.19.5 Valo Health Recent Development
11.20 Envisagenics
11.20.1 Envisagenics Company Detail
11.20.2 Envisagenics Business Overview
11.20.3 Envisagenics Artificial Intelligence-driven Drug Development Introduction
11.20.4 Envisagenics Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.20.5 Envisagenics Recent Development
11.21 Euretos
11.21.1 Euretos Company Detail
11.21.2 Euretos Business Overview
11.21.3 Euretos Artificial Intelligence-driven Drug Development Introduction
11.21.4 Euretos Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.21.5 Euretos Recent Development
11.22 BioAge Labs
11.22.1 BioAge Labs Company Detail
11.22.2 BioAge Labs Business Overview
11.22.3 BioAge Labs Artificial Intelligence-driven Drug Development Introduction
11.22.4 BioAge Labs Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.22.5 BioAge Labs Recent Development
11.23 Iktos
11.23.1 Iktos Company Detail
11.23.2 Iktos Business Overview
11.23.3 Iktos Artificial Intelligence-driven Drug Development Introduction
11.23.4 Iktos Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.23.5 Iktos Recent Development
11.24 BioSymetrics
11.24.1 BioSymetrics Company Detail
11.24.2 BioSymetrics Business Overview
11.24.3 BioSymetrics Artificial Intelligence-driven Drug Development Introduction
11.24.4 BioSymetrics Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.24.5 BioSymetrics Recent Development
11.25 Evaxion Biotech
11.25.1 Evaxion Biotech Company Detail
11.25.2 Evaxion Biotech Business Overview
11.25.3 Evaxion Biotech Artificial Intelligence-driven Drug Development Introduction
11.25.4 Evaxion Biotech Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.25.5 Evaxion Biotech Recent Development
11.26 Aria Pharmaceuticals
11.26.1 Aria Pharmaceuticals Company Detail
11.26.2 Aria Pharmaceuticals Business Overview
11.26.3 Aria Pharmaceuticals Artificial Intelligence-driven Drug Development Introduction
11.26.4 Aria Pharmaceuticals Revenue in Artificial Intelligence-driven Drug Development Business (2019-2024)
11.26.5 Aria Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

IBM
Exscientia
Google(Alphabet)
Microsoft
Atomwise
Schrodinger
Aitia
Insilico Medicine
NVIDIA
XtalPi
BPGbio
Owkin
CytoReason
Deep Genomics
Cloud Pharmaceuticals
BenevolentAI
Cyclica
Verge Genomics
Valo Health
Envisagenics
Euretos
BioAge Labs
Iktos
BioSymetrics
Evaxion Biotech
Aria Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.